Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie recently completed a clinical study titled A Phase 3b/4 Randomized, Blinded, Treat-to-Target and Dose-Flexibility Study of Upadacitinib in Adult Subjects With Moderate to Severe Atopic Dermatitis. The study aimed to evaluate the dosing flexibility and effectiveness of upadacitinib, an oral tablet, in treating moderate to severe atopic dermatitis in adults. This condition often requires systemic treatment due to its inflammatory nature.
The intervention being tested is upadacitinib, a drug already approved for various immune-mediated inflammatory diseases. The study involved administering upadacitinib in different dosages to assess its impact on disease activity and adverse events.
The study was designed as a randomized, sequential intervention model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors were blinded. The primary purpose was treatment-focused, aiming to determine the effectiveness of upadacitinib in reducing eczema severity.
The study began on May 29, 2023, and was completed with results first submitted on June 30, 2025. The last update was submitted on July 28, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for investors and stakeholders.
The completion of this study could positively influence AbbVie’s stock performance by showcasing the potential of upadacitinib in treating atopic dermatitis, potentially expanding its market share. This could also impact investor sentiment favorably, especially in the context of competition within the pharmaceutical industry.
The study is now completed, with further details available on the ClinicalTrials portal.